Butenandt O
Kinderklinik im Dr. von Haunerschen Kinderspital, Universitat München.
Fortschr Med. 1996 Jun 10;114(16):201-4.
The availability of unlimited amounts of recombinant human growth hormone (rhGH) has now made it possible to investigate its growth-promoting effect in children in whom growth hormone production is not deficient. In girls suffering from the Ullrich Turner syndrome, treatment with rhGH increases final height by some 6 to 8 cm. An increase in growth rate has also been observed in children with renal insufficiency, and in children with intrauterine growth retardation. Favourable results have also been reported in children receiving glucocorticoids for such chronic conditions as rheumatoid arthritis, and in youngsters with hypochondroplasia. In a further group of children with various disorders an improvement in the growth rate has been observed, although nothing can yet be said about the outcome in terms of final height. To achieve an increase in growth rate, pharmacological doses of growth hormone higher than those used in children with growth hormone deficiency are necessary. For this reason, the risk of unwanted side effects might be higher than in the latter.
现在，有了无限量的重组人生长激素（rhGH），就有可能研究其对生长激素分泌并不缺乏的儿童的促生长作用。在患有乌尔里希·特纳综合征的女孩中，用rhGH治疗可使最终身高增加约6至8厘米。在肾功能不全的儿童以及宫内生长迟缓的儿童中也观察到生长速度加快。对于因类风湿性关节炎等慢性疾病接受糖皮质激素治疗的儿童以及软骨发育不全的青少年，也有良好效果的报道。在另一组患有各种疾病的儿童中，观察到生长速度有所改善，不过就最终身高而言，目前还无法得出结论。为了提高生长速度，需要使用高于生长激素缺乏儿童所用剂量的药理剂量的生长激素。因此，出现不良副作用的风险可能比后者更高。
